I respectfully disagree with your contention above. In all likelihood, generic Lovenox will have a lower patient co-pay than branded Lovenox in most insurance plans and formularies. I doubt that many docs would opt to bar generic substitution explicitly despite knowing that they would be subjecting patients to a higher medical bill than necessary.
If I’m wrong and it turns out that many docs do check the “do not substitute” box on their Lovenox prescriptions, NVS has ample resources to rectify the situation. Regards, Dew